Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results

doi:10.5501/wjv.v6.i4.59

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11261)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-8) series.

Item

Count

PDF

619

WORD

361

HTML

4361

Figures (1-2)

189

Tables (1-8)

209

Sum=5739

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

1198

Download

1395

Sum=2593

Publishing Process of This Article

Item

Count

Browse

1140

Download

1789

Sum=2929

Nov 12, 2017 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Virol. Nov 12, 2017; 6(4): 59-72
Published online Nov 12, 2017. doi: 10.5501/wjv.v6.i4.59

Full Size Figure Download Figure

Figure 1 Outline of the study cohort. Five hundred and eight patients initiated treatment. The number of patients with confirmed outcomes [sustained virological response (SVR) 12 or non-SVR12], the number with imputed outcomes, and the number who were lost to follow-up on each of three regimens are indicated. SVR: Sustained virological response; SMV: Simeprevir; SOF: Sofosbuvir; RBV: Ribavirin; PEG: Pegylated interferon.

Citation: Bichoupan K, Tandon N, Crismale JF, Hartman J, Del Bello D, Patel N, Chekuri S, Harty A, Ng M, Sigel KM, Bansal MB, Grewal P, Chang CY, Leong J, Im GY, Liu LU, Odin JA, Bach N, Friedman SL, Schiano TD, Perumalswami PV, Dieterich DT, Branch AD. Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World J Virol 2017; 6(4): 59-72
URL: https://www.wjgnet.com/2220-3249/full/v6/i4/59.htm
DOI: https://dx.doi.org/10.5501/wjv.v6.i4.59